Skip to main
EQ

Equillium Inc (EQ) Stock Forecast & Price Target

Equillium Inc (EQ) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Equillium is a promising biotechnology company with a strong focus on developing innovative therapies for severe autoimmune and inflammatory disorders. The company's lead therapeutic candidate, EQ504, has shown impressive results in clinical trials, including a 50.8% clinical remission rate and a 41.5% endoscopic remission rate in patients with ulcerative colitis. These results, along with the company's mission to develop life-changing therapeutics, point to a positive outlook for Equillium's future success. Furthermore, the company's management has a clear and cohesive strategy in place, with a single operating and reportable segment focused solely on advancing EQ504 through clinical development. With a strong scientific foundation and a promising pipeline of treatments in development, Equillium presents potential for significant growth and investment opportunities in the biotechnology sector.

Bears say

Equillium is facing several fundamental reasons for its negative outlook. Firstly, its primary product, EQ504, is unproven and has not entered human testing, making it a potential financial risk. Additionally, there is no guarantee that the drug will replicate the target engagement, safety profile, or efficacy observed in clinical trials with similar agents. The company's reliance on a single product and its lack of near-term financing options also add to this negative outlook.

Equillium Inc (EQ) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Equillium Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Equillium Inc (EQ) Forecast

Analysts have given Equillium Inc (EQ) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Equillium Inc (EQ) has a Strong Buy consensus rating as of Jul 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Equillium Inc (EQ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.